57 active not recruiting. 57 Phase 2, 7 Phase 1, 7 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 57 | Active not recruiting 57 |
| Phase 1 | 7 | Active not recruiting 7 |
| Phase 3 | 7 | Active not recruiting 7 |
Follow Pt: new trials by email Literature Review of Pt trials Research Report on Pt
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer Biopsy, Biospecimen Collection, Computed Tomography - Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma | Phase 2 | Active not recruiting | Mayo Clinic | 24 | 2024-12-06 | 2026-06-18 |
| Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma Biospecimen Collection, Computed Tomography, Echocardiography - B-Cell Non-Hodgkin Lymphoma | Phase 2 | Active not recruiting | Northwestern University | 11 | 2024-09-30 | 2026-09-14 |
| Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Multiple Myeloma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 58 | 2024-07-23 | 2026-09-25 |
| Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX Trial Avelumab, Biopsy Procedure, Biospecimen Collection - Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8 | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 50 | 2024-05-21 | 2026-07-31 |
| Risk Stratified De-escalated Hormone Therapy With Radiation Therapy for the Treatment of Prostate Cancer Abiraterone Acetate, Biospecimen Collection, Computed Tomography - Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma | Phase 2 | Active not recruiting | Mayo Clinic | 110 | 2024-04-22 | 2026-09-25 |
| Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Pancreatic Cancer and Peritoneal Metastasis Cisplatin, Hyperthermic Intraperitoneal Chemotherapy, Nab-paclitaxel - Metastatic Pancreatic Carcinoma, Stage IV Pancreatic Cancer AJCC v8 | Phase 2 | Active not recruiting | Mayo Clinic | 40 | 2024-02-15 | 2026-10-15 |
| Pembrolizumab Followed by Chemotherapy for the Treatment of Patients With Classical Hodgkin Lymphoma Biopsy, Biospecimen Collection, Computed Tomography - Classic Hodgkin Lymphoma | Phase 2 | Active not recruiting | Northwestern University | 30 | 2024-02-06 | 2026-07-13 |
| Sacituzumab Govitecan for the Treatment for Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma Biopsy, Biospecimen Collection, Computed Tomography - Locally Advanced Cholangiocarcinoma, Metastatic Cholangiocarcinoma | Phase 2 | Active not recruiting | University of Kansas Medical Center | 15 | 2024-02-01 | 2026-02-24 |
| Lenalidomide and Epcoritamab for the Treatment of Previously Untreated Follicular Lymphoma Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Follicular Lymphoma | Phase 2 | Active not recruiting | City of Hope Medical Center | 29 | 2024-01-24 | 2026-08-26 |
| Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer Atezolizumab, Biospecimen Collection, Capecitabine - Clinical Stage I Gastric Cancer AJCC v8, Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8 | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 2 | 2023-12-06 | 2026-07-01 |
| Testing the Effect of M1774 on Hard-to-Treat Refractory SPOP-mutant Prostate Cancer Biopsy Procedure, Biospecimen Collection, Computed Tomography - Castration-Resistant Prostate Carcinoma, Metastatic Castration-Resistant Prostate Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 20 | 2023-10-16 | 2026-07-31 |
| Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma Biopsy, Biospecimen Collection, Carboplatin - Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 2 | Active not recruiting | David Bond, MD | 37 | 2023-06-29 | 2026-07-20 |
| Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation Biopsy, Biospecimen Collection, Bone Marrow Biopsy - Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia | Phase 2 | Active not recruiting | City of Hope Medical Center | 9 | 2023-06-02 | 2026-10-01 |
| Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial Chemotherapy, Computed Tomography, Fludeoxyglucose F-18 - Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8 | Phase 2 | Active not recruiting | ECOG-ACRIN Cancer Research Group | 235 | 2023-05-10 | 2026-10-19 |
| FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer Balstilimab, Bevacizumab, Biospecimen Collection - Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma | Phase 1 / Phase 2 | Active not recruiting | City of Hope Medical Center | 20 | 2023-05-03 | 2026-09-01 |
| Short Course Radiotherapy for the Treatment of Patients With Glioblastoma, SAGA Study Accelerated Hypofractionated Radiation Therapy, Computed Tomography, Fluorodopa F 18 - Glioblastoma | Phase 2 | Active not recruiting | Mayo Clinic | 170 | 2023-03-23 | 2026-07-30 |
| Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers Atezolizumab, Bevacizumab, Biospecimen Collection - Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma | Phase 2 / Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 430 | 2023-03-13 | 2026-11-03 |
| Pirtobrutinib and Venetoclax With MRD Detection for Previously Untreated Chronic Lymphocytic Leukemia Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Active not recruiting | Mayo Clinic | 72 | 2023-01-31 | 2026-02-12 |
| Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Acalabrutinib, Durvalumab, Venetoclax - Chronic Lymphocytic Leukemia, Richter Syndrome | Phase 2 | Active not recruiting | Mayo Clinic | 27 | 2023-01-05 | 2026-10-05 |
| Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors Atezolizumab, Biospecimen Collection, Computed Tomography - Atypical Teratoid/Rhabdoid Tumor, Epithelioid Sarcoma | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 86 | 2022-11-17 | 2026-07-14 |
Showing 20 of 57. Sign in to see all of them.
Rhabdoid Tumor (5) · Sarcoma (5) · Ependymoma (4) · Glioma (4) · Hepatoblastoma (4) · Histiocytosis, Langerhans-Cell (4) · Lymphoma, Non-Hodgkin (4) · Medulloblastoma (4) · Neuroblastoma (4) · Neuroectodermal Tumors, Primitive, Peripheral (4) · Oropharyngeal Neoplasms (4) · Prostatic Neoplasms (4) · Wilms Tumor (4) · Breast Neoplasms (3) · Carcinoma, Non-Small-Cell Lung (3)
National Cancer Institute (NCI) (33) · Mayo Clinic (10) · City of Hope Medical Center (3) · ECOG-ACRIN Cancer Research Group (3) · NRG Oncology (3) · Northwestern University (2) · David Bond, MD (1) · University of Kansas Medical Center (1) · University of Washington (1)
United States (57) · Canada (10) · Puerto Rico (7) · Australia (5) · Hong Kong (2) · China (1) · Ireland (1) · Singapore (1) · Switzerland (1) · Taiwan (1)
Aarti Bhatia (1) · Ahmad Tarhini (1) · Alain P Algazi (1) · Alan L Ho (1) · Alexander N Shoushtari (1) · Alice Lee (1) · Andrea B Apolo (1) · Andrea T Franson (1) · Ashish Chintakuntlawar, MBBS, PhD (1) · Brian J. Davis, M.D. (1) · Bridget F Koontz (1) · Carlos E. Vargas, M.D. (1) · Catherine S Diefenbach (1) · Christine M Bestvina (1)
PMID 31401903, PMID 32853585, PMID 33020646, PMID 33591402, PMID 33604999, PMID 34416167, PMID 34486544, PMID 34634256, PMID 34686472, PMID 35353553, PMID 35613998, PMID 37505794, PMID 37596449, PMID 38573872, PMID 38737792, PMID 38934093, PMID 39415930, PMID 39571596, PMID 39938471, PMID 40813711, PMID 41047708, PMID 41166674, PMID 41611998, PMID 41662628, PMID 42191879, PMID 42507969, PMID 42660130, PMID 42686334, PMID 42867148
U10CA180820 (9), U10CA180821 (4), U10CA180868 (4), U10CA180886 (4), U10CA180888 (4), UM1CA186709 (4), P30CA033572 (3), UM1CA186689 (3), P30CA060553 (2), UM1CA186644 (2), UM1CA186688 (2), UM1CA186691 (2), UM1CA186712 (2), P01CA084203 (1), P30CA006516 (1)